Outcomes

At the conclusion of the 3rd Joint Medicines Policy Conference, the Department of Health and Ageing (DOHA) and Medicines Australia agreed to work collaboratively on the following Conference Outcomes:

Health Technology Assessment (HTA) continuum

  • Develop policies recognising HTA as a continuum not just the start of the process
  • Include community interactions at various points in the whole HTA continuum.
  • Recognise the challenges of the continuum of HTA and the need for broad consultation
  • Examine current HTA methodologies and develop new methodologies
  • Use of observational datasets

Improving data linkages

  • Develop a strategic plan for using datasets across health, including:
  • Developing policy settings that enable data linkages notwithstanding the need to maintain
  • security of access to data and the need to address privacy issues (de-identification of data)
  • Building on currently available data sets;
  • Researching ways to improve data collection, storage and security;
  • Applying universal data standards across health data sets; and
  • Building on the lessons from the Department of Veterans’ Affairs (DVA) MATES program

Further improve consumer involvement

  • Better awareness of how to participate in the HTA processes, including:
  • Promoting health literacy;
  • Consumer inputs in designing product familiarisation programs;
  • Improving creativity in engaging with consumers; and
  • Using new media technologies to engage across the spectrum including with the grass roots

Building on post marketing surveillance initiatives

  • Develop strategies to improve consumer input into the post marketing surveillance process
  • Better consumer driven adverse event reporting systems
  • Develop subsequent work programs
  • Improve the quality of data collection
  • Develop strategies to utilise new and current observational datasets

Addressing privacy issues

  • Explore ways to address privacy concerns for the Personally Controlled Electronic Health Records (PCEHR)
  • Examine ways to improve confidence that will encourage participation (opting in)
  • Protection of consumers, their data and developing anti-discriminatory provisions
  • Review the cost of no action (opting out)
  • Examine the need to build the integrity and importance of post market surveillance and how the PCEHR will contribute to meet societal needs

Access for special patient groups

  • Explore the role of NHMRC in researching the needs of special patient groups
  • Policies to improve compassionate access
  • Need for greater coordination between Industry, Govt. Agencies and consumers
  • Address workforce issues – special patient groups (Indigenous, Paediatric etc)
  • Recognition of Paediatric issues and explore ways to improve data sets including registries

Future National Medicines Policy

  • Broader policy debate exploring the inclusion of Complementary medicines, devices into the National Medicines Policy
  • Re-define ‘sustainability’ (less about the $) to reflect the ethos and the underlying philosophy of equity of access
  • Continue to monitor key drivers

Innovation and HTA

  • Develop ways of improve Govt-Industry dialogue in targeting innovation
  • Identify and monitor factors influencing drug development, including
  • Identify and develop ways to address market failures
  • Explore opportunities for public-private partnerships to promote drug development
  • Explore ways to maintain policy predictability in recognition of long drug development cycles

Joint Medicines Policy Conference 2011 Outcomes  39k